Moderna stock crash proves markets trade on yield not hope
Moderna stock dropped after leaked trial data missed market expectations, showing that speculative capital demands precise yield over corporate secrecy.
By Bram de Vries ·
moderna — Lorien Times
The Trump administration slanders science, and the AMA fights back
In my father’s printing shop in Bologna, we understood that a page is only as reliable as the press that produces it. If the machine is misaligned, the truth becomes a smudge.
By Elena Rossi ·
Beyond the Science: Cost and Complexity of Personalized mRNA Vaccines
While individualized mRNA vaccines show immense promise for cancer, their economic viability and operational scaling remain massive hurdles.
By Grant Colby ·
New mRNA vaccine could reduce the recurrence and spread of skin cancer
The market’s reaction to Moderna and Merck's personalized mRNA vaccine for melanoma—a spectacular 177% surge in Moderna’s stock, according to CNBC—is pure adrenaline.
By Dana Whitfield ·
Moderna/Merck stock frenzy ignores universal rights for mRNA therapy
The sheer velocity of the stock market is always the most exhausting part of any major announcement.
By Aoife Gallagher ·
Moderna's 130% gain must prove US manufacturing for Medicare access
I’ve spent my life scoring things in payroll. I track whether a promise lands on a spreadsheet: who gets hired, at what wage, and if the work remains there five years from now.
By Ray Dombrowski ·
The strange reason flu shots have been so hard to improve
The whole performance around flu shots feels less like public health advice and more like an exercise in regulatory theater.
By Ray Dombrowski ·
FDA whiplash for Moderna’s mFlusiva obscures a scientific asset
The details are always the same when Washington decides to play God with basic medicine. First, there’s the technological breakthrough—in this case, Moderna's mFlusiva, an mRNA-based flu vaccine.
By Grant Colby ·
The Ebola crisis proves tech speed is not systemic strength in DRC
The news cycle has an alarming habit: when a deadly pathogen flares up in the Global South, the response is not measured competence but breathless technological pronouncements.
By Klaus Berger ·